Unknown

Dataset Information

0

Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.


ABSTRACT: Animal models are essential to study novel antiretroviral drugs, resistance-associated mutations (RAMs), and treatment strategies. Bictegravir (BIC) is a novel potent integrase strand transfer inhibitor (INSTI) that has shown promising results against HIV-1 infection in vitro and in vivo and against clinical isolates with resistance against INSTIs. BIC has a higher genetic barrier to the development of resistance than two clinically approved INSTIs, termed raltegravir and elvitegravir. Another clinically approved INSTI, dolutegravir (DTG) also possesses a high genetic barrier to resistance, while a fourth compound, termed cabotegravir (CAB), is currently in late phases of clinical development. Here we report the susceptibilities of simian immunodeficiency virus (SIV) and HIV-1 integrase (IN) mutants containing various RAMs to BIC, CAB, and DTG. BIC potently inhibited SIV and HIV-1 in single cycle infection with 50% effective concentrations (EC50s) in the low nM range. In single cycle SIV infections, none of the E92Q, T97A, Y143R, or N155H substitutions had a significant effect on susceptibility to BIC (?4-fold increase in EC50), whereas G118R and R263K conferred ?14-fold and ?6-fold increases in EC50, respectively. In both single and multiple rounds of HIV-1 infections, BIC remained active against the Y143R, N155H, R263K, R263K/M50I, and R263K/E138K mutants (?4-fold increase in EC50). In multiple rounds of infection, the G140S/Q148H combination of substitutions decreased HIV-1 susceptibility to BIC 4.8-fold compared to 16.8- and 7.4-fold for CAB and DTG, respectively. BIC possesses an excellent resistance profile in regard to HIV and SIV and could be useful in nonhuman primate models of HIV infection.

SUBMITTER: Hassounah SA 

PROVIDER: S-EPMC5700299 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

Hassounah Said A SA   Alikhani Ahmad A   Oliveira Maureen M   Bharaj Simrat S   Ibanescu Ruxandra-Ilinca RI   Osman Nathan N   Xu Hong-Tao HT   Brenner Bluma G BG   Mesplède Thibault T   Wainberg Mark A MA  

Antimicrobial agents and chemotherapy 20171122 12


Animal models are essential to study novel antiretroviral drugs, resistance-associated mutations (RAMs), and treatment strategies. Bictegravir (BIC) is a novel potent integrase strand transfer inhibitor (INSTI) that has shown promising results against HIV-1 infection <i>in vitro</i> and <i>in vivo</i> and against clinical isolates with resistance against INSTIs. BIC has a higher genetic barrier to the development of resistance than two clinically approved INSTIs, termed raltegravir and elvitegra  ...[more]

Similar Datasets

| S-EPMC5956922 | biostudies-literature
| S-EPMC6496081 | biostudies-literature
| S-EPMC6153831 | biostudies-literature
| S-EPMC5118987 | biostudies-literature
| S-EPMC4328052 | biostudies-literature
| S-EPMC5790636 | biostudies-literature
| S-EPMC6585996 | biostudies-literature
| S-EPMC8092912 | biostudies-literature
| S-EPMC7449158 | biostudies-literature
| S-EPMC3983366 | biostudies-other